TY  - JOUR
AU  - Kivitz, Alan
AU  - Olech, Ewa
AU  - Borofsky, Michael A
AU  - Zazueta, Beatriz
AU  - Navarro-Sarabia, Federico
AU  - Radominski, Sebastião C
AU  - Merrill, Joan T
AU  - Pacheco-Tena, César
AU  - Pei, Jinglan
AU  - Nasmyth-Miller, Clare
AU  - Pope, Janet E
PY  - 2017
DO  - 10.3899/jrheum.161539
SN  - 0315-162X
UR  - http://hdl.handle.net/10668/11917
T2  - The Journal of rheumatology
AB  - To evaluate the longterm efficacy and safety of subcutaneous tocilizumab (TCZ-SC) every 2 weeks (q2w) over 2 years in patients with rheumatoid arthritis who have an inadequate response to disease-modifying antirheumatic drugs (DMARD). Patients (n =...
LA  - en
KW  - BIOLOGICAL THERAPY
KW  - CLINICAL TRIAL
KW  - RHEUMATOID ARTHRITIS
KW  - Adult
KW  - Aged
KW  - Antibodies, Monoclonal, Humanized
KW  - Antirheumatic Agents
KW  - Arthritis, Rheumatoid
KW  - Dose-Response Relationship, Drug
KW  - Double-Blind Method
KW  - Drug Therapy, Combination
KW  - Drug Tolerance
KW  - Female
KW  - Follow-Up Studies
KW  - Humans
KW  - Infections
KW  - Injection Site Reaction
KW  - Injections, Subcutaneous
KW  - Male
KW  - Middle Aged
KW  - Remission Induction
KW  - Severity of Illness Index
KW  - Treatment Outcome
TI  - Two-year Efficacy and Safety of Subcutaneous Tocilizumab in Combination with Disease-modifying Antirheumatic Drugs Including Escalation to Weekly Dosing in Rheumatoid Arthritis.
TY  - research article
VL  - 45
ER  -